NCT05751343View on ClinicalTrials.gov

TACE-HAIC Plus Atezolizumab and Bevacizumab for Unresectable Advanced HCC: a Phase 2 Clinical Trial

PHASE2RecruitingINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

March 9, 2023

Primary Completion Date

August 28, 2024

Study Completion Date

September 28, 2025

Conditions
Hepatocellular Carcinoma
Interventions
DRUG

TACE-HACI, plus atezolizumab-bevacizumab

transartery chemoembolization and artery infusion of FOLFOX, simultaneously followed by intravenous atezolizumab plus bevacizumab

Trial Locations (1)

510060

RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER